CONTROLLED TRIAL OF STREPTOKINASE AND HEPARIN IN ACUTE MYOCARDIAL INFARCTION

N. Dioguardi, A. Lotto, G. F. Levi, M. Rota, C. Proto, P. M. Mannucci, P. Rossi, B. Lomanto, G. Mattei, G. Fiorelli, A. Agostoni

Research output: Contribution to journalArticle

Abstract

A controlled clinical trial comparing streptokinase plus heparin with heparin alone in acute myocardial infarction of less than 12 hours' duration has been conducted in three hospitals in Italy. All the patients were managed in coronary-care units with continuous electrocardiographic monitoring and intensive medical and nursing care. On admission the patients were randomly allocated to heparin or to streptokinase-both drugs being given in standard doses. 321 patients were included in the trial, and survivors were followed up for 40 days; 164 were treated with streptokinase and 157 formed the control group. The total mortality in the streptokinase group was 19 patients (11·6%) and in the control group 18 (11·5%). The frequency of heart-failure, shock, arrhythmias, and non-transmural infarctions did not differ significantly between the two treatment groups. These results do not suggest that streptokinase therapy would reduce the morbidity and the mortality in patients with acute myocardial infarction treated in coronary-care units with the dosage and selection of cases used in this trial.

Original languageEnglish
Pages (from-to)891-895
Number of pages5
JournalLancet
Volume298
Issue number7730
DOIs
Publication statusPublished - Oct 23 1971

Fingerprint

Streptokinase
Heparin
Myocardial Infarction
Coronary Care Units
Critical Care Nursing
Control Groups
Mortality
Patient Admission
Controlled Clinical Trials
Infarction
Italy
Survivors
Cardiac Arrhythmias
Shock
Heart Failure
Morbidity
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dioguardi, N., Lotto, A., Levi, G. F., Rota, M., Proto, C., Mannucci, P. M., ... Agostoni, A. (1971). CONTROLLED TRIAL OF STREPTOKINASE AND HEPARIN IN ACUTE MYOCARDIAL INFARCTION. Lancet, 298(7730), 891-895. https://doi.org/10.1016/S0140-6736(71)92501-3

CONTROLLED TRIAL OF STREPTOKINASE AND HEPARIN IN ACUTE MYOCARDIAL INFARCTION. / Dioguardi, N.; Lotto, A.; Levi, G. F.; Rota, M.; Proto, C.; Mannucci, P. M.; Rossi, P.; Lomanto, B.; Mattei, G.; Fiorelli, G.; Agostoni, A.

In: Lancet, Vol. 298, No. 7730, 23.10.1971, p. 891-895.

Research output: Contribution to journalArticle

Dioguardi, N, Lotto, A, Levi, GF, Rota, M, Proto, C, Mannucci, PM, Rossi, P, Lomanto, B, Mattei, G, Fiorelli, G & Agostoni, A 1971, 'CONTROLLED TRIAL OF STREPTOKINASE AND HEPARIN IN ACUTE MYOCARDIAL INFARCTION', Lancet, vol. 298, no. 7730, pp. 891-895. https://doi.org/10.1016/S0140-6736(71)92501-3
Dioguardi, N. ; Lotto, A. ; Levi, G. F. ; Rota, M. ; Proto, C. ; Mannucci, P. M. ; Rossi, P. ; Lomanto, B. ; Mattei, G. ; Fiorelli, G. ; Agostoni, A. / CONTROLLED TRIAL OF STREPTOKINASE AND HEPARIN IN ACUTE MYOCARDIAL INFARCTION. In: Lancet. 1971 ; Vol. 298, No. 7730. pp. 891-895.
@article{69acc93106f74bce93d7c157f18b2af9,
title = "CONTROLLED TRIAL OF STREPTOKINASE AND HEPARIN IN ACUTE MYOCARDIAL INFARCTION",
abstract = "A controlled clinical trial comparing streptokinase plus heparin with heparin alone in acute myocardial infarction of less than 12 hours' duration has been conducted in three hospitals in Italy. All the patients were managed in coronary-care units with continuous electrocardiographic monitoring and intensive medical and nursing care. On admission the patients were randomly allocated to heparin or to streptokinase-both drugs being given in standard doses. 321 patients were included in the trial, and survivors were followed up for 40 days; 164 were treated with streptokinase and 157 formed the control group. The total mortality in the streptokinase group was 19 patients (11·6{\%}) and in the control group 18 (11·5{\%}). The frequency of heart-failure, shock, arrhythmias, and non-transmural infarctions did not differ significantly between the two treatment groups. These results do not suggest that streptokinase therapy would reduce the morbidity and the mortality in patients with acute myocardial infarction treated in coronary-care units with the dosage and selection of cases used in this trial.",
author = "N. Dioguardi and A. Lotto and Levi, {G. F.} and M. Rota and C. Proto and Mannucci, {P. M.} and P. Rossi and B. Lomanto and G. Mattei and G. Fiorelli and A. Agostoni",
year = "1971",
month = "10",
day = "23",
doi = "10.1016/S0140-6736(71)92501-3",
language = "English",
volume = "298",
pages = "891--895",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "7730",

}

TY - JOUR

T1 - CONTROLLED TRIAL OF STREPTOKINASE AND HEPARIN IN ACUTE MYOCARDIAL INFARCTION

AU - Dioguardi, N.

AU - Lotto, A.

AU - Levi, G. F.

AU - Rota, M.

AU - Proto, C.

AU - Mannucci, P. M.

AU - Rossi, P.

AU - Lomanto, B.

AU - Mattei, G.

AU - Fiorelli, G.

AU - Agostoni, A.

PY - 1971/10/23

Y1 - 1971/10/23

N2 - A controlled clinical trial comparing streptokinase plus heparin with heparin alone in acute myocardial infarction of less than 12 hours' duration has been conducted in three hospitals in Italy. All the patients were managed in coronary-care units with continuous electrocardiographic monitoring and intensive medical and nursing care. On admission the patients were randomly allocated to heparin or to streptokinase-both drugs being given in standard doses. 321 patients were included in the trial, and survivors were followed up for 40 days; 164 were treated with streptokinase and 157 formed the control group. The total mortality in the streptokinase group was 19 patients (11·6%) and in the control group 18 (11·5%). The frequency of heart-failure, shock, arrhythmias, and non-transmural infarctions did not differ significantly between the two treatment groups. These results do not suggest that streptokinase therapy would reduce the morbidity and the mortality in patients with acute myocardial infarction treated in coronary-care units with the dosage and selection of cases used in this trial.

AB - A controlled clinical trial comparing streptokinase plus heparin with heparin alone in acute myocardial infarction of less than 12 hours' duration has been conducted in three hospitals in Italy. All the patients were managed in coronary-care units with continuous electrocardiographic monitoring and intensive medical and nursing care. On admission the patients were randomly allocated to heparin or to streptokinase-both drugs being given in standard doses. 321 patients were included in the trial, and survivors were followed up for 40 days; 164 were treated with streptokinase and 157 formed the control group. The total mortality in the streptokinase group was 19 patients (11·6%) and in the control group 18 (11·5%). The frequency of heart-failure, shock, arrhythmias, and non-transmural infarctions did not differ significantly between the two treatment groups. These results do not suggest that streptokinase therapy would reduce the morbidity and the mortality in patients with acute myocardial infarction treated in coronary-care units with the dosage and selection of cases used in this trial.

UR - http://www.scopus.com/inward/record.url?scp=0015237714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015237714&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(71)92501-3

DO - 10.1016/S0140-6736(71)92501-3

M3 - Article

C2 - 4106657

AN - SCOPUS:0015237714

VL - 298

SP - 891

EP - 895

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7730

ER -